A clinical-stage biotech using AI and automation to discover drugs, with several compounds in trials for rare diseases.
No product revenue; money comes from collaborations with Bayer and Takeda, but losses are deep—net margin is -945.92%.
Proprietary AI platform and data from partnerships create barriers, but heavy reliance on partners and no approved drugs weaken it.
Key events, in time order
Q2 results released; loss narrowed YoY but missed consensus; FY2026 cash opex guidance cut to $375M
3,234,866 inducement RSUs granted to 24 new hires on Jul 27, vesting quarterly
Two independent sources highlight industry growth and competitive pressure on Recursion
Dario Amodei states biotech renaissance driven by AI, expects many diseases to be cured, and highlights $RXRX as a key AI healthcare play
None yet
None yet
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
